메뉴 건너뛰기




Volumn 310, Issue 23, 2013, Pages 2510-2522

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial

(24)  Feres, Fausto a   Costa, Ricardo A a   Abizaid, Alexandre a   Leon, Martin B b   Marin Neto, J Antônio c   Botelho, Roberto V d   King III, Spencer B e   Negoita, Manuela f   Liu, Minglei f   De Paula, J Eduardo T g   Mangione, José A h   Meireles, George X i   Castello, Hélio J j   Nicolela, Eduardo L k   Perin, Marco A l   Devito, Fernando S m   Labrunie, André n   Salvadori, Décio h   Gusmão, Marcos o   Staico, Rodolfo a   more..


Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ZOTAROLIMUS;

EID: 84890373385     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282183     Document Type: Article
Times cited : (620)

References (43)
  • 1
    • 33847736642 scopus 로고    scopus 로고
    • Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    • Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998-1008.
    • (2007) N Engl J Med , vol.356 , Issue.10 , pp. 998-1008
    • Stone, G.W.1    Moses, J.W.2    Ellis, S.G.3
  • 2
    • 33847167065 scopus 로고    scopus 로고
    • Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study
    • Daemen J,Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667-678.
    • (2007) Lancet , vol.369 , Issue.9562 , pp. 667-678
    • Daemen, J.1    Wenaweser, P.2    Tsuchida, K.3
  • 3
    • 33846125284 scopus 로고    scopus 로고
    • Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    • Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297(2):159-168.
    • (2007) JAMA , vol.297 , Issue.2 , pp. 159-168
    • Eisenstein, E.L.1    Anstrom, K.J.2    Kong, D.F.3
  • 4
    • 0035908781 scopus 로고    scopus 로고
    • Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
    • Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
    • Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533.
    • (2001) Lancet , vol.358 , Issue.9281 , pp. 527-533
    • Mehta, S.R.1    Yusuf, S.2    Peters, R.J.3
  • 5
    • 0037145863 scopus 로고    scopus 로고
    • Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
    • CREDO Investigators
    • Steinhubl SR, Berger PB, Mann JT III, et al CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-2420.
    • (2002) JAMA , vol.288 , Issue.19 , pp. 2411-2420
    • Steinhubl, S.R.1    Berger, P.B.2    Mann III, J.T.3
  • 6
    • 83155180256 scopus 로고    scopus 로고
    • 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
    • published correction appears in Circulation. 2012;125(8):e412
    • Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [published correction appears in Circulation. 2012;125(8):e412]. Circulation. 2011;124(23):e574-e651.
    • (2011) Circulation , vol.124 , Issue.23
    • Levine, G.N.1    Bates, E.R.2    Blankenship, J.C.3
  • 7
    • 34547860049 scopus 로고    scopus 로고
    • Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment
    • Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745-754.
    • (2007) Circulation , vol.116 , Issue.7 , pp. 745-754
    • Airoldi, F.1    Colombo, A.2    Morici, N.3
  • 8
    • 70349896556 scopus 로고    scopus 로고
    • Stent thrombosis after drug-eluting stent implantation: Incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
    • Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714-2721.
    • (2009) Eur Heart J , vol.30 , Issue.22 , pp. 2714-2721
    • Schulz, S.1    Schuster, T.2    Mehilli, J.3
  • 9
    • 61349100778 scopus 로고    scopus 로고
    • Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation
    • Roy P, Bonello L, Torguson R, et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol. 2009;103(6):801-805.
    • (2009) Am J Cardiol , vol.103 , Issue.6 , pp. 801-805
    • Roy, P.1    Bonello, L.2    Torguson, R.3
  • 10
    • 77951001904 scopus 로고    scopus 로고
    • Duration of dual antiplatelet therapy after implantation of drug-eluting stents
    • Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362(15):1374-1382.
    • (2010) N Engl J Med , vol.362 , Issue.15 , pp. 1374-1382
    • Park, S.J.1    Park, D.W.2    Kim, Y.H.3
  • 11
    • 84856452781 scopus 로고    scopus 로고
    • Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study
    • Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505-513.
    • (2012) Circulation , vol.125 , Issue.3 , pp. 505-513
    • Gwon, H.C.1    Hahn, J.Y.2    Park, K.W.3
  • 12
    • 84860135329 scopus 로고    scopus 로고
    • Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial
    • Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators
    • Valgimigli M, Campo G, Monti M, et al Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015-2026.
    • (2012) Circulation , vol.125 , Issue.16 , pp. 2015-2026
    • Valgimigli, M.1    Campo, G.2    Monti, M.3
  • 13
    • 84867050148 scopus 로고    scopus 로고
    • A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
    • RESET Investigators
    • Kim BK, Hong MK, Shin DH, et al RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340- 1348.
    • (2012) J Am Coll Cardiol , vol.60 , Issue.15 , pp. 1340-1348
    • Kim, B.K.1    Hong, M.K.2    Shin, D.H.3
  • 14
    • 33645861080 scopus 로고    scopus 로고
    • Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    • CHARISMA Investigators
    • Bhatt DL, Fox KA, Hacke W, et al CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
    • (2006) N Engl J Med , vol.354 , Issue.16 , pp. 1706-1717
    • Bhatt, D.L.1    Fox, K.A.2    Hacke, W.3
  • 15
    • 77951868945 scopus 로고    scopus 로고
    • Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease
    • SPIRIT IV Investigators
    • Stone GW, Rizvi A, Newman W, et al; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663-1674.
    • (2010) N Engl J Med , vol.362 , Issue.18 , pp. 1663-1674
    • Stone, G.W.1    Rizvi, A.2    Newman, W.3
  • 16
    • 84876413538 scopus 로고    scopus 로고
    • The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent
    • ENDEAVOR IV Investigators
    • Kirtane AJ, Leon MB, Ball MW, et al; ENDEAVOR IV Investigators. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013;6(4):325-333.
    • (2013) JACC Cardiovasc Interv , vol.6 , Issue.4 , pp. 325-333
    • Kirtane, A.J.1    Leon, M.B.2    Ball, M.W.3
  • 17
    • 84867890841 scopus 로고    scopus 로고
    • Everolimus-eluting stent versus bare-metal stent in ST-segment elevationmyocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial
    • Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevationmyocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial. Lancet. 2012;380(9852):1482-1490.
    • (2012) Lancet , vol.380 , Issue.9852 , pp. 1482-1490
    • Sabate, M.1    Cequier, A.2    Iñiguez, A.3
  • 18
    • 84867843842 scopus 로고    scopus 로고
    • EXAMINATION of new drug-eluting stents-top of the class!
    • Bhatt DL. EXAMINATION of new drug-eluting stents-top of the class! Lancet. 2012;380(9852):1453-1455.
    • (2012) Lancet , vol.380 , Issue.9852 , pp. 1453-1455
    • Bhatt, D.L.1
  • 19
    • 84862128532 scopus 로고    scopus 로고
    • Shortand long-term outcomes with drug-eluting and bare-metal coronary stents: Amixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials
    • Bangalore S, Kumar S, Fusaro M, et al. Shortand long-term outcomes with drug-eluting and bare-metal coronary stents: amixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873-2891.
    • (2012) Circulation , vol.125 , Issue.23 , pp. 2873-2891
    • Bangalore, S.1    Kumar, S.2    Fusaro, M.3
  • 20
    • 72149124227 scopus 로고    scopus 로고
    • Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization
    • Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS. Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. JACC Cardiovasc Interv. 2009;2(12):1279-1285.
    • (2009) JACC Cardiovasc Interv , vol.2 , Issue.12 , pp. 1279-1285
    • Kandzari, D.E.1    Angiolillo, D.J.2    Price, M.J.3    Teirstein, P.S.4
  • 21
    • 78651430525 scopus 로고    scopus 로고
    • Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents
    • Mauri L, Massaro JM, Jiang S, et al. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. JACC Cardiovasc Interv. 2010;3(12):1240-1249.
    • (2010) JACC Cardiovasc Interv , vol.3 , Issue.12 , pp. 1240-1249
    • Mauri, L.1    Massaro, J.M.2    Jiang, S.3
  • 22
    • 84870293994 scopus 로고    scopus 로고
    • Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: Rationale and design of a large-scale, randomized, multicenter study
    • Feres F, Costa RA, Bhatt DL, et al. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study. Am Heart J. 2012;164(6):810-816.
    • (2012) Am Heart J , vol.164 , Issue.6 , pp. 810-816
    • Feres, F.1    Costa, R.A.2    Bhatt, D.L.3
  • 23
    • 77954399153 scopus 로고    scopus 로고
    • Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity: Addendum to the historical MI definitions used in stent studies
    • Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity: addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010;5(7):871-874.
    • (2010) EuroIntervention , vol.5 , Issue.7 , pp. 871-874
    • Vranckx, P.1    Cutlip, D.E.2    Mehran, R.3
  • 24
    • 34247558672 scopus 로고    scopus 로고
    • Clinical end points in coronary stent trials: A case for standardized definitions
    • Academic Research Consortium
    • Cutlip DE, Windecker S, Mehran R, et al Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
    • (2007) Circulation , vol.115 , Issue.17 , pp. 2344-2351
    • Cutlip, D.E.1    Windecker, S.2    Mehran, R.3
  • 25
    • 35348913868 scopus 로고    scopus 로고
    • Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial
    • Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol. 2007;100(9):1364-1369.
    • (2007) Am J Cardiol , vol.100 , Issue.9 , pp. 1364-1369
    • Feit, F.1    Voeltz, M.D.2    Attubato, M.J.3
  • 26
    • 0026521772 scopus 로고
    • Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion
    • Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee
    • Topol EJ, Armstrong P, Van de Werf F, et al Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol. 1992;19(6):1123-1128.
    • (1992) J Am Coll Cardiol , vol.19 , Issue.6 , pp. 1123-1128
    • Topol, E.J.1    Armstrong, P.2    Van De Werf, F.3
  • 27
    • 72149103553 scopus 로고    scopus 로고
    • E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry
    • Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT; E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv. 2009;2(12):1227-1235.
    • (2009) JACC Cardiovasc Interv , vol.2 , Issue.12 , pp. 1227-1235
    • Lotan, C.1    Meredith, I.T.2    Mauri, L.3    Liu, M.4    Rothman, M.T.5
  • 28
    • 77954392890 scopus 로고    scopus 로고
    • Comparison of zotarolimus-eluting and everolimus-eluting coronary stents
    • Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136-146.
    • (2010) N Engl J Med , vol.363 , Issue.2 , pp. 136-146
    • Serruys, P.W.1    Silber, S.2    Garg, S.3
  • 29
    • 84883745765 scopus 로고    scopus 로고
    • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    • EXAMINE Investigators
    • White WB, Cannon CP, Heller SR, et al EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.
    • (2013) N Engl J Med , vol.369 , Issue.14 , pp. 1327-1335
    • White, W.B.1    Cannon, C.P.2    Heller, S.R.3
  • 30
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • SAVOR-TIMI 53 Steering Committee and Investigators
    • Scirica BM, Bhatt DL, Braunwald E, et al SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.
    • (2013) N Engl J Med , vol.369 , Issue.14 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3
  • 31
    • 84875596758 scopus 로고    scopus 로고
    • Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
    • PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators
    • Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? a pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34(12):909-919.
    • (2013) Eur Heart J , vol.34 , Issue.12 , pp. 909-919
    • Valgimigli, M.1    Borghesi, M.2    Tebaldi, M.3    Vranckx, P.4    Parrinello, G.5    Ferrari, R.6
  • 32
    • 67650755016 scopus 로고    scopus 로고
    • Safety and efficacy of drug-eluting and baremetal stents: Comprehensive meta-analysis of randomized trials and observational studies
    • Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and baremetal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.
    • (2009) Circulation , vol.119 , Issue.25 , pp. 3198-3206
    • Kirtane, A.J.1    Gupta, A.2    Iyengar, S.3
  • 33
    • 84867746832 scopus 로고    scopus 로고
    • Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial
    • PROTECT Steering Committee and Investigators
    • Camenzind E, Wijns W, Mauri L, et al PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012;380(9851):1396-1405.
    • (2012) Lancet , vol.380 , Issue.9851 , pp. 1396-1405
    • Camenzind, E.1    Wijns, W.2    Mauri, L.3
  • 34
    • 84867874811 scopus 로고    scopus 로고
    • Endothelial progenitor cell response to antiproliferative drug exposure
    • Banerjee S, Xu H, Fuh E, et al. Endothelial progenitor cell response to antiproliferative drug exposure. Atherosclerosis. 2012;225(1):91-98.
    • (2012) Atherosclerosis , vol.225 , Issue.1 , pp. 91-98
    • Banerjee, S.1    Xu, H.2    Fuh, E.3
  • 35
    • 77954746572 scopus 로고    scopus 로고
    • Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents
    • ODESSA Trial Investigators
    • Guagliumi G, Musumeci G, Sirbu V, et al ODESSA Trial Investigators. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv. 2010;3(5):531-539.
    • (2010) JACC Cardiovasc Interv , vol.3 , Issue.5 , pp. 531-539
    • Guagliumi, G.1    Musumeci, G.2    Sirbu, V.3
  • 36
    • 72149133094 scopus 로고    scopus 로고
    • Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial
    • Kim JS, Jang IK, Fan C, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv. 2009;2(12):1240-1247.
    • (2009) JACC Cardiovasc Interv , vol.2 , Issue.12 , pp. 1240-1247
    • Kim, J.S.1    Jang, I.K.2    Fan, C.3
  • 37
    • 77951618598 scopus 로고    scopus 로고
    • Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents
    • Ben-Dor I, Torguson R, Scheinowitz M, et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J. 2010;159(5):871-875.
    • (2010) Am Heart J , vol.159 , Issue.5 , pp. 871-875
    • Ben-Dor, I.1    Torguson, R.2    Scheinowitz, M.3
  • 38
    • 79959550517 scopus 로고    scopus 로고
    • Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium
    • Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-2747.
    • (2011) Circulation , vol.123 , Issue.23 , pp. 2736-2747
    • Mehran, R.1    Rao, S.V.2    Bhatt, D.L.3
  • 39
    • 77956634931 scopus 로고    scopus 로고
    • Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
    • EVENT Investigators
    • Berger PB, Kleiman NS, Pencina MJ, et al EVENT Investigators. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv. 2010;3(9):920-927.
    • (2010) JACC Cardiovasc Interv , vol.3 , Issue.9 , pp. 920-927
    • Berger, P.B.1    Kleiman, N.S.2    Pencina, M.J.3
  • 40
    • 84885441282 scopus 로고    scopus 로고
    • Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents
    • Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013;310(14):1462-1472.
    • (2013) JAMA , vol.310 , Issue.14 , pp. 1462-1472
    • Hawn, M.T.1    Graham, L.A.2    Richman, J.S.3    Itani, K.M.4    Henderson, W.G.5    Maddox, T.M.6
  • 41
    • 63149181056 scopus 로고    scopus 로고
    • Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study
    • Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators
    • Byrne RA, Schulz S, Mehilli J, et al; Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J. 2009;157(4):620-624.
    • (2009) Am Heart J , vol.157 , Issue.4 , pp. 620-624
    • Byrne, R.A.1    Schulz, S.2    Mehilli, J.3
  • 42
    • 78650097647 scopus 로고    scopus 로고
    • Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or baremetal stent placement for the treatment of coronary artery lesions
    • Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or baremetal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160(6):1035-1041.
    • (2010) Am Heart J , vol.160 , Issue.6 , pp. 1035-1041
    • Mauri, L.1    Kereiakes, D.J.2    Normand, S.L.3
  • 43
    • 84886258945 scopus 로고    scopus 로고
    • Thrombus aspiration during ST-segment elevation myocardial infarction
    • published online September 1, 2013
    • Fröbert O, Lagerqvist B, Olivecrona GK, et al Thrombus aspiration during ST-segment elevation myocardial infarction [published online September 1, 2013]. N Engl J Med.
    • N Engl J Med
    • Fröbert, O.1    Lagerqvist, B.2    Olivecrona, G.K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.